Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 10 of 10 publications.
Skip to main content
Krege JH, Gilsenan AW, Komacko JL, Kellier-Steele N. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. J Bone Miner Res. 2022 Aug 14;6(9):e10665. doi: 10.1002/jbm4.10665
Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul;194(1):1-11. doi: 10.1007/s10549-021-06469-0
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
Kellier N, Krohn K, Gilsenan AW, Harris DH, Andrews EB, Massica D. Forteo voluntary patient registry: 3-Year progress on a prospective osteosarcoma surveillance study. Poster presented at the American Society for Bone and Mineral Research Annual Meeting; October 6, 2013.
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Gilsenan A, Andrews E, Hollis KA. Characterization of current risk evaluation and mitigation strategies. Poster presented at the 26th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 25, 2010. Brighton, United Kingdom. [abstract] Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S1):S100. doi: 10.1002/pds.2019
Martin RD, Gilsenan AW, Wu Y, Midkiff KD, Masica DN. Long-term post-marketing studies: flexibility, perseverance and patience. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Burdett AN, Gard C, Gilsenan A, Hirji Z, Raskin J, Miller D. Prevalence and costs associated with treating depression with painful physical symptoms in a Canadian administrative services database. Poster presented at the 21st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2005. Nashville, TN.
Burdett AN, Gard CC, Longo CJ, Raskin J, Gilsenan A, Hopkins JS, Miller DP. Prevalence and costs of difficult-to-treat depression in a Canadian claims database. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux.
Gilsenan AW, Hopkins JS, Sherrill EH, Corey-Lisle PK, Longo CJ, Raskin J. Prevalence and costs of treatment-resistant depression in a Canadian claims database. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting; 2002.